Abstract
The evidence base that underpins the pharmacological management of the epilepsies is not earth shattering. Most randomised, double-blind trials of the newer antiepileptic drugs (AEDs) have been done by the pharmaceutical industry for regulatory purposes with the primary aim of obtaining a licence. Add-on studies usually investigate a range of doses versus placebo for efficacy in patients with refractory epilepsy, but few patients become free from seizures. The results of head-to-head comparisons in patients with newly diagnosed epilepsy have been more interesting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
